Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
EZH2
Name:
enhancer of zeste 2 polycomb repressive complex 2 subunit
Location:
07q36.1
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | View | |
| NCT03618485 | Registry of Patients With MPNs in Taiwan | View | |
| NCT03280888 | Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia CMML | View | |
| NCT06484985 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors | View | |
| NCT04173585 | TEAM-Trial Targeting Epigenetic Therapy Resistance in AML With Bortezomib | View | |
| NCT05467748 | EZH2 Inhibitor Tulmimetostat and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | View | |
| NCT04917042 | Tazemetostat in Malignant Peripheral Nerve Sheath Tumors | View | |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With RelapsedRefractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation | View | |
| NCT05965505 | Study of AXT-1003 in Adult Subjects With RelapsedRefractory Non-Hodgkin Lymphomas | View | |
| NCT04225429 | Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | View | |
| NCT04407741 | Phase ⅠⅡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | View | |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | View | |
| NCT02860286 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | View | |
| NCT03456726 | Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkins Lymphoma With EZH2 Gene Mutation | View | |
| NCT01271764 | The Association of G9a Protein and Outcome of Patients With Endometrial Cancer | View | |
| NCT04842877 | Study of Valemetostat Tosylate as a Single Agent in Patients With RelapseRefractory B-cell Lymphoma | View | |
| NCT05228158 | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 EZH2 Gene Mutation in Japan | View | |
| NCT02082977 | A Study to Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With RelapsedRefractory Diffuse Large B Cell Lymphoma Transformed Follicular Lymphoma Other Non-Hodgkins Lymphomas Solid Tumors and Multiple Myeloma | View | |
| NCT03460977 | Mevrometostat Treatment of RelapsedRefractory SCLC Castration Resistant Prostate Cancer and Follicular Lymphoma | View | |
| NCT03480646 | ProSTAR A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | View | |
| NCT02395601 | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | View | |
| NCT05567679 | A Study of Tazemetostat Tazverik Before Prostatectomy in Men With Prostate Cancer | View | |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | View | |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With EZH2 SMARCB1 or SMARCA4 Gene Mutations A Pediatric MATCH Treatment Trial | View | |
| NCT03525795 | ORIOn-E A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | View | |
| NCT03603951 | A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms | View | |
| NCT05551936 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | View | |
| NCT06392230 | A Study to Learn How the Medicine Called 14C PF-06821497 is Taken up Into and Removed From the Body | View | |
| NCT04762160 | SYMPHONY-2 A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With RelapsedRefractory Follicular Lymphoma | View | |
| NCT04215822 | PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia | View | |
| NCT05023655 | Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | View | |
| NCT04224493 | A Study to Assess the Efficacy Safety Pharmacodynamics and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With RelapsedRefractory Follicular Lymphoma | View | |
| NCT04279327 | Cell Block Immunohistochemistry in Effusion Cytology | View | |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | View | |
| NCT04557956 | Testing the Addition of the Anti-cancer Drug Tazemetostat to the Usual Treatment Dabrafenib and Trametinib for Metastatic Melanoma That Has Progressed on the Usual Treatment | View | |
| NCT05983965 | Study of Tazemetostat in Lymphoid Malignancies | View | |
| NCT05994235 | Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | View | |
| NCT06519526 | Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With RelapsedRefractory Peripheral T Cell Lymphoma | View | |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | View | |
| NCT05656222 | Irinotecan and Anlotinib for Epithelioid Sarcoma | View | |
| NCT05816850 | Multilayer Biological Characterization of Advanced Follicular Lymphoma a Translational Study From FIL_FOLL12 Trial | View | |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer The PREDICT Trial | View | |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments KEYNOTE F19 | View | |
| NCT02491840 | Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas a Pilot Study | View | |
| NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | View | |
| NCT03311815 | Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing NGS in Patients Diagnosed With Acute Myeloid Leukemia | View | |
| NCT04104776 | A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | View |